Modulating Th2 Cell Immunity for the Treatment of Asthma. - Abstract - Europe PMC
![Supplemental Materials for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5710422a-7b47-4eeb-ac52-48a5a375394e/gr1_lrg.jpg "Supplemental Materials for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents")
Supplemental Materials for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Mechanism of action of mepolizumab, reslizumab, and benralizumab. | Download Scientific Diagram
Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation - ScienceDirect
Mechanism of action of mepolizumab, reslizumab, and benralizumab. | Download Scientific Diagram
Mechanism of action of mepolizumab, reslizumab, and benralizumab. | Download Scientific Diagram
IJMS | Free Full-Text | Monoclonal Antibodies and Airway Diseases | HTML
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 | DDDT
Mechanism of action of mepolizumab, reslizumab, and benralizumab. | Download Scientific Diagram
Farmaceutisch_tijdschrift_voor_België_Nr_1_maart_2019 - Page 50
Reslizumab Overview - Creative Biolabs
How do the IL-5 inhibitors Cinqair, Fasenra, and Nucala work? -vasculitides: a vasculitis blog
Mepolizumab
Self-Administered Mepolizumab in the Management of Severe Asthma: Usab | PPA
Reslizumab | New Drug Approvals
Eosinophil (eos) trafficking and maturation in asthma. Notes:... | Download Scientific Diagram
The mechanism of action of therapies targeting iL-5 and its receptor.... | Download Scientific Diagram
From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases - Pavord - 2022 - Allergy - Wiley Online Library
EAACI Biologicals Guidelines—Recommendations for severe asthma - Agache - 2021 - Allergy - Wiley Online Library
Reslizumab: Uses, Interactions, Mechanism of Action | DrugBank Online
Mechanism of action of mepolizumab, reslizumab, and benralizumab. | Download Scientific Diagram
How do the IL-5 inhibitors Cinqair, Fasenra, and Nucala work? -vasculitides: a vasculitis blog
JCM | Free Full-Text | The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians | HTML
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
IJMS | Free Full-Text | Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity? | HTML
